Prevalence and prognosis of high-risk myocardial infarction patient candidates to extended antiplatelet therapy.

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Marrugat de la Iglesia, Jaumeca
• dc.contributor.author Elosua Llanos, Robertoca
• dc.contributor.author Sayols, Sergica
• dc.contributor.author Dégano, Irene R.ca
• dc.date.accessioned 2016-07-25T08:37:53Z
• dc.date.issued 2016
• dc.description.abstract INTRODUCTION AND OBJECTIVES: Secondary prevention in myocardial infarction patients is paramount to prevent recurrences. Dual antiplatelet therapy has been shown to reduce the risk of subsequent events up to 1 year and beyond in the PEGASUS-TIMI 54 trial. This study aimed to estimate the annual number of myocardial infarction patients with PEGASUS characteristics in Spain and to analyze short- and long-term outcomes in these patients. METHODS: The number of myocardial infarction patients was estimated assuming a Poisson distribution. Myocardial infarction incidence and mortality rates obtained from population registries (IBERICA and REGICOR) were properly adjusted. The proportion of myocardial infarction patients with PEGASUS characteristics was estimated with a REGICOR cohort of consecutive patients from 2003-2009 (n=1391). This cohort follow-up was used to compare the occurrence of reinfarction and death at 1 year and at the end of the follow-up (4.7 years) in patients with and without PEGASUS characteristics by Cox regression. RESULTS: The estimated annual number of stable myocardial infarction patients aged ≥ 50 years and without bleeding events was 41 311. Of these, 22 493 had at least 1 PEGASUS characteristic (diabetes, previous myocardial infarction, or chronic kidney disease). At 4.7 years of follow-up, having any PEGASUS characteristic or age ≥ 65 years was associated with a higher risk of cardiovascular and all-cause death in adjusted analyses (hazard ratio=3.44 and 2.21, 95% confidence interval, 1.22-9.74 and 1.11-4.42, respectively). CONCLUSIONS: In Spain, more than 50% of the stable myocardial infarction patients aged ≥ 50 years are estimated to have at least 1 PEGASUS characteristic, which substantially increases the long-term risk of cardiovascular and all-cause death.ca
• dc.description.sponsorship The REGICOR AMI Registry was supported by the Instituto de Salud Carlos III-FEDER (grant numbers RD06/0009, RD12/0042, FIS-90/0672, FIS-93/0568, FIS 94/0539, FIS96/0026-01, FIS99/0655, FIS99/0013-01, FIS 99/9342, PI081327, PI11/01801, CP12/03287 [MG], and IFI14/00007 [SSB]), the Catalan Agency for Management of University and Research Grants (grant numbers 2005SGR00577, 2009SGR1195, 2014SGR240), Fundació La Marató TV3 (grant number ID #081630) and Agència d’Informació, Avaluació i Qualitat en Salut (grant number AATRM 034/33/02). I.R. Dégano was funded by the RECERCAIXA Program, Obra Social ‘‘La Caixa’’ (grant number RE087465).
• dc.format.mimetype application/pdfca
• dc.identifier.citation Marrugat J, Elosua R, Grau M, Sayols-Baixeras S, Dégano IR. Prevalence and prognosis of high-risk myocardial infarction patient candidates to extended antiplatelet therapy. Rev Esp Cardiol (Engl Ed). 2016 May;69(5):480-7. doi: 10.1016/j.rec.2015.12.022ca
• dc.identifier.doi http://dx.doi.org/10.1016/j.rec.2015.12.022
• dc.identifier.issn 1885-5857
• dc.identifier.uri http://hdl.handle.net/10230/27112
• dc.language.iso engca
• dc.publisher Elsevierca
• dc.relation.ispartof Revista Española de Cardiología. 2016 May;69(5):480-7
• dc.rights © Elsevier http://dx.doi.org/10.1016/j.rec.2015.12.022ca
• dc.rights.accessRights info:eu-repo/semantics/openAccessca
• dc.subject.other Malalties coronàriesca
• dc.subject.other Diabetisca
• dc.subject.other Infart de miocardica
• dc.title Prevalence and prognosis of high-risk myocardial infarction patient candidates to extended antiplatelet therapy.ca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/acceptedVersionca